Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Multicolor flow cytometric analysis of LAP expression on human peripheral blood lymphocytes. Human peripheral blood mononuclear cells were activated (24 h) with plate-bound Purified NA/LE Mouse Anti-Human CD3 (Cat. No. 555329) and Purified NA/LE Mouse Anti-Human CD28 (Cat. No. 555725) antibodies. The cells were harvested and stained with PerCP-Cy™ 5.5 Mouse Anti-Human CD4 (Cat. No. 341654) and either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Left Panel) or BD Horizon™ PE-CF594 Mouse Anti-Human LAP (Cat. No. 562490; Right Panel) antibodies. The cells were then fixed and stained with the Alexa Fluor® 647 Mouse Anti-Human FoxP3 (Cat. No. 560889/560045) antibody according to the recommended protocol. Two-color flow cytometric dot plots showing the correlated expression patterns of FoxP3 versus LAP (or Ig isotype control staining) were derived from CD4 positive-gated cells with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Multicolor flow cytometric analysis of LAP expression on human peripheral blood lymphocytes. Human peripheral blood mononuclear cells were activated (24 h) with plate-bound Purified NA/LE Mouse Anti-Human CD3 (Cat. No. 555329) and Purified NA/LE Mouse Anti-Human CD28 (Cat. No. 555725) antibodies. The cells were harvested and stained with PerCP-Cy™ 5.5 Mouse Anti-Human CD4 (Cat. No. 341654) and either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Left Panel) or BD Horizon™ PE-CF594 Mouse Anti-Human LAP (Cat. No. 562490; Right Panel) antibodies. The cells were then fixed and stained with the Alexa Fluor® 647 Mouse Anti-Human FoxP3 (Cat. No. 560889/560045) antibody according to the recommended protocol. Two-color flow cytometric dot plots showing the correlated expression patterns of FoxP3 versus LAP (or Ig isotype control staining) were derived from CD4 positive-gated cells with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Multicolor flow cytometric analysis of LAP expression on human peripheral blood lymphocytes. Human peripheral blood mononuclear cells were activated (24 h) with plate-bound Purified NA/LE Mouse Anti-Human CD3 (Cat. No. 555329) and Purified NA/LE Mouse Anti-Human CD28 (Cat. No. 555725) antibodies. The cells were harvested and stained with PerCP-Cy™ 5.5 Mouse Anti-Human CD4 (Cat. No. 341654) and either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Left Panel) or BD Horizon™ PE-CF594 Mouse Anti-Human LAP (Cat. No. 562490; Right Panel) antibodies. The cells were then fixed and stained with the Alexa Fluor® 647 Mouse Anti-Human FoxP3 (Cat. No. 560889/560045) antibody according to the recommended protocol. Two-color flow cytometric dot plots showing the correlated expression patterns of FoxP3 versus LAP (or Ig isotype control staining) were derived from CD4 positive-gated cells with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Multicolor flow cytometric analysis of LAP expression on human peripheral blood lymphocytes. Human peripheral blood mononuclear cells were activated (24 h) with plate-bound Purified NA/LE Mouse Anti-Human CD3 (Cat. No. 555329) and Purified NA/LE Mouse Anti-Human CD28 (Cat. No. 555725) antibodies. The cells were harvested and stained with PerCP-Cy™ 5.5 Mouse Anti-Human CD4 (Cat. No. 341654) and either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Left Panel) or BD Horizon™ PE-CF594 Mouse Anti-Human LAP (Cat. No. 562490; Right Panel) antibodies. The cells were then fixed and stained with the Alexa Fluor® 647 Mouse Anti-Human FoxP3 (Cat. No. 560889/560045) antibody according to the recommended protocol. Two-color flow cytometric dot plots showing the correlated expression patterns of FoxP3 versus LAP (or Ig isotype control staining) were derived from CD4 positive-gated cells with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Multicolor flow cytometric analysis of LAP expression on human peripheral blood lymphocytes. Human peripheral blood mononuclear cells were activated (24 h) with plate-bound Purified NA/LE Mouse Anti-Human CD3 (Cat. No. 555329) and Purified NA/LE Mouse Anti-Human CD28 (Cat. No. 555725) antibodies. The cells were harvested and stained with PerCP-Cy™ 5.5 Mouse Anti-Human CD4 (Cat. No. 341654) and either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Left Panel) or BD Horizon™ PE-CF594 Mouse Anti-Human LAP (Cat. No. 562490; Right Panel) antibodies. The cells were then fixed and stained with the Alexa Fluor® 647 Mouse Anti-Human FoxP3 (Cat. No. 560889/560045) antibody according to the recommended protocol. Two-color flow cytometric dot plots showing the correlated expression patterns of FoxP3 versus LAP (or Ig isotype control staining) were derived from CD4 positive-gated cells with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Multicolor flow cytometric analysis of LAP expression on human peripheral blood lymphocytes. Human peripheral blood mononuclear cells were activated (24 h) with plate-bound Purified NA/LE Mouse Anti-Human CD3 (Cat. No. 555329) and Purified NA/LE Mouse Anti-Human CD28 (Cat. No. 555725) antibodies. The cells were harvested and stained with PerCP-Cy™ 5.5 Mouse Anti-Human CD4 (Cat. No. 341654) and either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Left Panel) or BD Horizon™ PE-CF594 Mouse Anti-Human LAP (Cat. No. 562490; Right Panel) antibodies. The cells were then fixed and stained with the Alexa Fluor® 647 Mouse Anti-Human FoxP3 (Cat. No. 560889/560045) antibody according to the recommended protocol. Two-color flow cytometric dot plots showing the correlated expression patterns of FoxP3 versus LAP (or Ig isotype control staining) were derived from CD4 positive-gated cells with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Suggested Staining Procedures for BD Horizon™ PE-CF594 Mouse Anti-Human LAP antibody:
1. Harvest PBMCs after stimulation (24 hours) with plate-bound Purified NA/LE Mouse Anti-Human CD3 (Cat. No. 555329) and Purified NA/LE Mouse Anti-Human CD28 (Cat. No. 555725) antibodies.
2. Wash the cells twice with stain buffer [eg. BD Pharmingen™ Stain Buffer (FBS), Cat. No. 554656].
3. Stain 1 × 10^6 cells with PerCP-Cy™ 5.5 Mouse Anti-Human CD4 (Cat. No. 341654) and either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292) or BD Horizon™ PE-CF594 Mouse Anti-Human LAP antibody (Cat. No. 562490) for 30 minutes on ice, protected from light.
4. Wash cells twice with stain buffer.
5. Stain cells for intracellular FoxP3 with Alexa Fluor® 647 Mouse Anti-Human FoxP3 antibody; refer to the Technical Data Sheets of Cat. No. 560889 or 560045 for a detailed protocol.
In brief,
a. Add 2 ml of 1 × FoxP3 buffer A to the cell pellet.
b. Centrifuge and incubate in 0.5 ml of buffer C for 30 minutes.
c. Wash cells twice with stain buffer and stain with fluorescent Anti-FoxP3 antibody for 30-45min.
d. Wash cells twice with stain buffer and analyze by flow cytometry.
The TW4-2F8 monoclonal antibody specifically binds to Latency-Associated Peptide (LAP), a component of the dimeric Transforming Growth Factor-beta 1 (TGF-β1) propeptide encoded by TGFB1. Prior to secretion, the dimeric LAP-TGF-β1 propeptide is cleaved resulting in a biologically inactive form of dimeric TGF-β1 that is noncovalently associated with dimeric LAP (latent TGF-β1). This complex may be expressed on the surface of TGF-β1-producing cells or be further processed by proteolytic removal of LAP to release the biologically active mature form of the soluble TGF-β1 homodimer. Platelets contain TGF-β1 and most nucleated cells, including tumor cells and cells that comprise the innate and adaptive immune system can produce TGF-β1. TGF-β1 is a potent multifunctional cytokine that regulates numerous processes including development, hematopoiesis, tissue remodeling, wound repair, and immunity as well as cancer and autoimmune diseases. Clone TW4-2F8 is routinely quality tested through intracellular staining of LAP in P3UI-TGFβ1 transfected cells.
This antibody is conjugated to BD Horizon™ PE-CF594, which has been developed exclusively by BD Biosciences as a better alternative to PE-Texas Red®. PE-CF594 excites and emits at similar wavelengths to PE-Texas Red® yet exhibits improved brightness and spectral characteristics. Due to PE having maximal absorption peaks at 496 nm and 564 nm, PE-CF594 can be excited by the blue (488-nm), green (532-nm) and yellow-green (561-nm) lasers and can be detected with the same filter set as PE-Texas Red® (eg 610/20-nm filter).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.